Business context and reporting period
Exelixis is an oncology-focused biotechnology company whose revenue is primarily driven by cabozantinib products, especially CABOMETYX. Its other marketed products include COMETRIQ, COTELLIC and MINNEBRO. The filing is a fiscal-year 2022 Form 10-K: the 52-week year ended December 30, 2022, with fiscal 2021 as the main comparison. This differs from the request metadata’s “2021 Q4.”
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $1,611.1 million | $1,435.0 million |
| Net product revenue | $1,401.2 million | $1,077.3 million |
| Operating income | $201.5 million | $286.7 million |
| Net income | $182.3 million | $231.1 million |
| Diluted EPS | $0.56 | $0.72 |
| Operating cash flow | $362.6 million | $400.8 million |
| Cash, cash equivalents, restricted cash and investments | $2,066.7 million | $1,854.9 million |
| Working capital | $1,294.4 million | $1,497.2 million |
Reported gross margin was 96% (95% in FY2021). Operating and net margins were approximately 12.5% and 11.3%, respectively, versus 20.0% and 16.1% in FY2021. Net cash used in investing activities was $524.4 million, mainly reflecting investment purchases and acquired in-process research and development; financing cash flow was positive $0.6 million. The balance sheet lists no borrowings; operating lease liabilities totaled $207.8 million. The filing states cash and operating resources are expected to fund operations for at least 12 months and the foreseeable future.
Material changes versus FY2021
- Total revenue rose 12%, while net product revenue increased 30%. CABOMETYX revenue grew 31% to $1,375.9 million; COMETRIQ revenue grew 9% to $25.3 million. Management attributed CABOMETYX growth principally to a 26% increase in units sold, supported by first-line RCC combination use and market-share gains, plus a 4% increase in average net selling price.
- License revenue declined 35% and collaboration services revenue declined 56%. FY2021 included substantial milestone revenue, including a $100 million Ipsen commercial milestone; FY2022 included $27 million of DTC regulatory milestones.
- R&D expense increased 29% to $891.8 million, and SG&A rose 14% to $459.9 million. Operating income fell 30% and net income fell 21%, despite higher revenue, as operating expenses grew faster.
- Operating cash flow declined to $362.6 million. Cash and investments increased, while working capital decreased, primarily due to long-term investment purchases and estimated tax payments.
Outlook, commentary, risks and unusual items
- Management expects FY2023 net product revenue to increase, citing market-share gains and anticipated price increases. It expects license revenue to decrease as fewer milestones are anticipated, partly offset by royalties; collaboration services revenue may also decrease. R&D and SG&A expenses are expected to rise. The company forecast an FY2023 effective tax rate of 20%–22%; it did not provide numerical revenue or earnings guidance.
- Pipeline progress is mixed: COSMIC-313 met its PFS endpoint, but the interim OS analysis showed no significant benefit; Exelixis said it would defer a potential submission pending further OS data. CONTACT-01 did not meet its OS endpoint, and the company does not plan to seek approval for cabozantinib plus atezolizumab in first-line HCC based on COSMIC-312 results. CONTACT-02 and CONTACT-03 results were anticipated in 2023. Zanzalintinib entered two Phase 3 trials; XB002 and XL102 remained in early-stage testing. XL114 development was discontinued in January 2023.
- Notable spending included $107.3 million of acquired in-process R&D expense. The company recognized a $60 million upfront payment for the CBX-12 acquisition right and a $30 million Catalent license payment; it also paid $40 million upfront under the Sairopa option agreement. A $12.5 million previously recorded development milestone expense was reversed after the program did not progress as expected.
- Generic competition is a material risk. In January 2023, a court ruling in MSN I barred FDA approval of MSN’s ANDA before August 2026, but found the proposed product did not infringe one asserted patent. Separate MSN litigation remained pending, Teva proceedings were stayed, and Cipla had submitted an ANDA. The company cautioned that litigation outcomes and generic-entry timing are uncertain.
- Other key risks include dependence on CABOMETYX, competition and changing treatment patterns, payer coverage and drug-pricing reforms (including the Inflation Reduction Act), clinical and regulatory uncertainty, reliance on partners and contract manufacturers, and cybersecurity and intellectual-property risks. The filing reports no material off-balance-sheet arrangements. Auditors issued unqualified opinions on the financial statements and internal controls; revenue recognition for product sales and receivables was identified as a critical audit matter.
Important facts for investors to verify
- Confirm the reporting-period mismatch: the supplied filing covers FY2022, not 2021 Q4.
- Track CABOMETYX sales growth, price and units, as well as rebates and discounts, which rose to $549.9 million from $375.7 million.
- Review subsequent clinical readouts and regulatory plans for CONTACT-02, CONTACT-03, COSMIC-313 and the zanzalintinib Phase 3 program.
- Monitor MSN, Teva and Cipla patent proceedings and the potential timing and commercial impact of generic CABOMETYX.
- Assess whether increasing R&D and commercialization spending remains supportable by operating cash flow and whether liquidity changes materially.